[1]REHERMANN B.Chronic infections with hepatotropic viruses:mechanisms of impairment of cellular immune responses[J].Semin Liver Dis, 2007, 27 (2) :152-160.
|
[2]KAWAI T, TAKAHASHI K, SATO S, et al.IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction[J].Nat Immunol, 2005, 6 (10) :981-988.
|
[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.
|
[4] BARRETT JC, FRY B, MALLER J, et al.Haploview:analysis and visualization of LD and haplotype maps[J].Bioinformatics, 2005, 21 (2) :263-265.
|
[5]GABRIEL SB, SCHAFFNER SF, NGUYEN H, et al.The structure of haplotype blocks in the human genome[J].Science, 2002, 296 (5576) :2225-2229.
|
[6]MEYLAN E, TSCHOPP J, KARIN M.Intracellular pattern recognition receptors in the host response[J].Nature, 2006, 442 (7098) :39-44.
|
[7]KUMAR H, KAWAI T, KATO H, et al.Essential role of IPS-1 in innate immune responses against RNA viruses[J].J Exp Med, 2006, 203 (7) :1795-1803.
|
[8]BARIL M, RACINE ME, PENIN F, et al.MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease[J].J Virol, 2009, 83 (3) :1299-1311.
|
[9]DENG L.Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments[J].J Clin Hepatol, 2012, 28 (6) :469-473. (in Chinese) 邓乐.乙型肝炎病毒基因型与抗病毒药物疗效关系的研究进展[J].临床肝胆病杂志, 2012, 28 (6) :469-473.
|
[10]BALACHANDRAN S, THOMAS E, BARBER GN.A FADD-dependent innate immune mechanism in mammalian cells[J].Nature, 2004, 432 (7015) :401-405.
|
[11]TAKAHASHI K, KAWAI T, KUMAR H, et al.Roles of caspase-8and caspase-10 in innate immune responses to double-stranded RNA[J].J Immunol, 2006, 176 (8) :4520-4524.
|
[12]BUSTER EH, HANSEN BE, LAU GK, et al.Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa[J].Gastroenterology, 2009, 137 (6) :2002-2009.
|
[13]SONNEVELD MJ, RIJCKBORST V, BOUCHER CA, et al.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J].Hepatology, 2010, 52 (4) :1251-1257.
|
[14]TSENG TC, YU ML, LIU CJ, et al.Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy[J].Antivir Ther, 2011, 16 (5) :629-637.
|
[15]HUANG YX, MA LN, CHEN XY, et al.Genetic polymorphisms of MxA protein and eIF-2a-reg2 and their responses to interferon treatment in patients with chronic hepatitis B[J].Chin J Hpeatol, 2007, 15 (3) :187-191. (in Chinese) 黄雁翔, 马丽娜, 陈新月, 等.粘病毒抵抗蛋白A和真核细胞起始因子2α调节区2基因多态性与慢性乙型肝炎干扰素治疗效果的相关性[J].中华肝脏病杂志, 2007, 15 (3) :187-191.
|
[16]WU X, ZHU X, ZHU S, et al.A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferonalpha treatment in chronic hepatitis B patients[J].Antiviral Res, 2009, 83 (3) :252-256.
|
[17]KING JK, YEH SH, LIN MW, et al.Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients:A pilot study[J].Hepatology, 2002, 36 (6) :1416-1424.
|
[18]LAMPERTICO P, VIGANOM, CHERONI C, et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology, 2013, 57 (3) :890-896.
|
[19]SONNEVELD MJ, WONG VW, WOLTMAN AM, et al.Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B[J].Gastroenterology, 2012, 142 (3) :513-520.
|